market

FDA Targets Homeopathic Weight Loss Products (HealthDay)

HealthDay – TUESDAY, Dec. 6 (HealthDay News) — U.S. officials on Tuesday said that they are taking action to remove controversial, unapproved and illegally labeled HCG weight loss products from the market.

View post: 
FDA Targets Homeopathic Weight Loss Products
(HealthDay)

market

Diabetes, Obesity After 60 May Drive Up Breast Cancer Risk (HealthDay)

HealthDay – TUESDAY, Dec. 6 (HealthDay News) — A woman’s risk of developing breast cancer appears to rise if she has diabetes or is obese after age 60, a new study indicates.

View original here: 
Diabetes, Obesity After 60 May Drive Up Breast Cancer Risk
(HealthDay)

market

FDA takes aim at "unproven" HCG weight-loss brands (Reuters)

Reuters – Regulators have taken first steps to remove from the market over-the-counter products containing HCG hormone, saying the homeopathic formulations fraudulently claim to produce weight loss and may pose serious health risks.

Originally posted here: 
FDA takes aim at "unproven" HCG weight-loss brands
(Reuters)

market

Experimental obesity drug beats placebo again (Reuters)

Reuters – The experimental weight-loss drug lorcaserin may spur modest weight loss without the heart risks of some older drugs, a new clinical trial confirms — though whether the medication will ever reach the market remains up in the air.

See the original post here:
Experimental obesity drug beats placebo again
(Reuters)

market

FDA declines to approve Orexigen diet drug (AP)

AP – Orexigen Therapeutics Inc. said Tuesday that U.S. health officials rejected its experimental weight loss pill Contrave and requested a new study of its potential heart risks, suggesting it will be years before a new drug for obesity reaches the market.

See the rest here:
FDA declines to approve Orexigen diet drug
(AP)

market

Health officials pull Abbott’s Meridia diet drug off market (Reuters)

Reuters – U.S. health officials have ordered Abbott Laboratories’ controversial weight loss drug Meridia off the market, and the company said it would comply even though it still thinks the drug is safe.

Excerpt from:
Health officials pull Abbott’s Meridia diet drug off market
(Reuters)

market

U.S. pulls Abbott’s Meridia diet drug off market (Reuters)

Reuters – U.S. health officials have ordered Abbott Laboratories’ controversial weight loss drug Meridia off the market, and the company said it would comply even though it still thinks the drug is safe.

View original here: 
U.S. pulls Abbott’s Meridia diet drug off market
(Reuters)

market

Obesity Among U.S. Workers Has Hefty Price Tag: Study (HealthDay)

HealthDay – FRIDAY, Oct. 8 (HealthDay News) — Obese workers cost U.S. employers $73.1 billion, a new study has found.

See the original post: 
Obesity Among U.S. Workers Has Hefty Price Tag: Study
(HealthDay)

market

Abbott diet drug study renews calls for U.S. ban (Reuters)

Reuters – A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market.

Originally posted here:
Abbott diet drug study renews calls for U.S. ban
(Reuters)

market

Corrected: Abbott’s diet drug study renews calls for U.S. ban (Reuters)

Reuters – A study funded by Abbott Laboratories offered more detailed evidence that its weight-loss drug Meridia increases heart risks, prompting renewed calls by consumer advocates and others to pull the drug from the market.

Original post: 
Corrected: Abbott’s diet drug study renews calls for U.S. ban
(Reuters)

Next Page »